Combinatorial fedratinib and venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high Flt3 expression.

Combination fedratinib and venetoclax reduces the survival and proliferation of FLT3 B-ALL in vitro. Gene set enrichment analysis of RNA from B-ALL treated with fedratinib and venetoclax identified dysregulation of pathways associated with apoptosis, DNA repair and proliferation.Combination fedratinib and venetoclax reduces the number of peripheral blood B-ALL blasts in vivo, improving overall survival while also increasing CD19 expression.